On April 12, 2024, AEON Biopharma, Inc. closed the transaction. The company issued one senior secured convertible note in the principal amount of $10,000,000 for a gross proceeds $10,000,000 in its final tranche. The Convertible Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date of April 12, 2027, unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | -2.94% | +1.23% | -77.08% |
May. 09 | AEON Biopharma, Inc. Provides Update on Development Pipeline | CI |
May. 03 | US Equity Markets Close Higher Friday Following Weak Jobs Report | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
110,600 KRW | -0.72% | -0.81% | 934M | ||
1.65 USD | -2.94% | +1.23% | 63.99M | ||
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-77.08% | 63.99M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-3.11% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |
- Stock Market
- Equities
- AEON Stock
- News AEON Biopharma, Inc.
- AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd